Vaccine maker Serum Institute CEO Adar Poonawalla in Fortune's global '40 under 40' list
Serum Institute of India (SII) CEO Adar Poonawalla is among the "emerging leaders" from across the world named by Fortune in its annual list of 40 most influential people under the age of 40. Byju Raveendran, co-founder of India's leading education technology company Byju's, Reliance Jio Board Directors Isha Ambani, and Akash Ambani are the other young guns from India to feature on the coveted list.
Apps ban to cost Chinese firms $200 million a year - and a future; PUBG to lose $100 million
With the raging concerns about data security and to safeguard the privacy of 130 crore Indians, the government of India has banned 224 Chinese apps including TikTok, PUBG Mobile, UC Browser, WeChat, and ShareIt, among others. The revenue generation of the banned apps from the Indian users is estimated at $200 million per year. For PUBG Mobile alone, the estimated revenue loss is estimated at $100 million a year.
US to permit Air India to conduct ground handling operations at airports
The United States has announced that it plans to restore Air India's ability to self-conduct its ground handling operations at American airports. Issuing an order in this regard, US Department of Transportation reversed its previous order of July 2019 that had suspended the right of Air India to self-handle at US airports.
Silver Lake in talks to buy $1 billion stake in Reliance Retail
Private equity firm Silver Lake Partners is in talks to invest $1 billion in the retail arm of India's Reliance Industries Ltd, the Financial Times reported on Thursday, citing people with direct knowledge of the matter. The investment, which would value Reliance Retail at about $57 billion, comes as the company is aiming to sell about 10% in new shares, the report added.
WHO recommends use of corticosteroids in severe COVID-19 cases
The World Health Organisation (WHO) has recommended doctors to use anti-inflammatory drug corticosteroids like dexamethasone and hydrocortisone in the treatment of COVID-19, following an analysis of various trials that proved to reduce deaths in critically ill patients by 20 per cent - a drop from two deaths per five patients to one in three. It has also warned the doctors not to use these drugs in non-severe COVID-19 patients.
Copyright©2021 Living Media India Limited. For reprint rights: Syndications Today